Both inhibitors synergize to more efficiently hinder the interaction between RhoA and LARG, intensifying the reduction of breast cancer proliferation and invasion and allowing their use in the treatment of RhoA-overexpressing tumors [150]. This evidence concerns the gene ARHGEF12 and breast carcinoma.